MDCX
Medicus Pharma Ltd. Common Stock
NASDAQ · Healthcare · Biotechnology · CA
$0.17
+0.88%Sep 3, 2026, 12:03 UTC
Medicus Pharma Ltd. signed a Co-Development and License Agreement with Pfizer Inc., under which Pfizer granted Medicus an exclusive worldwide license to develop, manufacture and commercialize PF-08046031 (CD228V), with Medicus paying a $12.0 million upfront fee and Pfizer paying a $2.0 million development funding payment.
Aug 13, 2026, 12:52 UTC
Medicus Pharma raised about $40 million through equity and debt financing during the first half of 2026.
Source:Aug 12, 2026, 18:00 UTC
Medicus Pharma Ltd. reported financial results for the three and six months ended June 30, 2026, and provided a corporate update on its development programs.
Aug 3, 2026, 14:02 UTC
Medicus Pharma announced that its chief medical officer, Dr Faisal Mehmud, will become CEO of its UK subsidiary Antev Limited on August 30, consolidating leadership of the Teverelix clinical programme.
Source:Jul 31, 2026, 13:32 UTC
Medicus Pharma received Investigational New Drug authorization from the United Arab Emirates Department of Health – Abu Dhabi for its Phase 2a PRECISION-E2 clinical study of Teverelix in women with moderate-to-severe symptomatic endometriosis.
Source:Jul 27, 2026, 12:17 UTC
Medicus Pharma received an FDA 'Study May Proceed' letter for its NDA-enabling registrational SkinJect study in patients with Gorlin syndrome.
Jul 18, 2026, 16:45 UTC
Medicus Pharma acquired the Teverelix development programme through its purchase of UK-based Antev.
Source:Jul 18, 2026, 16:45 UTC
Medicus Pharma received Institutional Review Board approval and US FDA acceptance for the revised clinical study protocol for Teverelix.
Source:Jul 16, 2026, 11:30 UTC
Medicus Pharma received positive FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in acute urinary retention.
Jun 20, 2026, 13:10 UTC
Medicus Pharma submitted a key European regulatory package to support the launch of a Phase 2b clinical study of Teverelix in advanced prostate cancer patients with elevated cardiovascular risk.
Source:Jun 15, 2026, 11:30 UTC
Medicus Pharma submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect in Gorlin Syndrome.
Jun 11, 2026, 12:53 UTC
Medicus Pharma submitted an Investigational New Drug application to Abu Dhabi's Department of Health for a Phase 2a clinical trial of Teverelix in endometriosis patients in the UAE.
Source:Jun 8, 2026, 12:51 UTC
Medicus Pharma filed a substantial modification application through the EU Clinical Trials Information System to advance a Phase 2b study of its prostate cancer drug Teverelix.
Source:Jun 6, 2026, 15:31 UTC
Medicus Pharma filed a registration study with the US Food and Drug Administration for its SkinJect program targeting Gorlin syndrome.
Source:Jun 3, 2026, 12:00 UTC
Medicus Pharma submitted Protocol SKNJCT-005 to the FDA under its existing IND for SkinJect® registrational development for Gorlin Syndrome.